Bayer eyes launch of heart, menopause relief drugs in 2025

London: Bayer said it is gearing up to launch two new pharmaceutical products this year, each with the potential to generate more than $1 billion in annual peak sales. The move comes as the German pharmaceutical and agricultural giant looks to bolster its drug portfolio amid mounting debt challenges.

In a statement, Bayer said it is preparing to introduce Beyonttra, also known as acoramidis, a treatment aimed at a condition that results in heart failure.

In "late summer" this year, it was eyeing the launch of menopause relief drug elinzanetant to ease hot flashes, it added.

As per Reuters, it said both had blockbuster potential, an industry term for potential peak annual sales of at least $1 billion.